This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuerer, H. M. Articles by Hunt, K. K. Search for Related Content PubMed PubMed Citation Articles by Kuerer, H. M. Articles by Hunt, K. K.

High and Differential Expression of HER-2/neu Extracellular Domain in Bilateral Ductal Fluids from Women with Unilateral Invasive Breast Cancer¹

Departments of Surgical Oncology [H. M. K., S. M. M., G. V. B., S. E. S., K. K. H.], Epidemiology [P. A. T.], Laboratory Medicine [H. A. F.], Pathology [S. K., N. S.], and Breast Medical Oncology [M. C.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Purpose: Overexpression of HER-2/neu is associated with aggressive diseaseand perhaps with increased risk of breast cancer when presentin benign breast tissue. Breast ductal fluid can be obtained from women by simple nipple aspiration and may be useful for analyzing the microenvironment of the breast.

Experimental Design: After obtaining informed consent, we prospectively compared the volume of fluid collected, protein concentration, and level of HER-2/neu expression in nipple aspiration fluid (NAF) samples from both breasts and serum samples in 65 patients with unilateral primary invasive breast cancer (median age, 54 years). HER-2/neu concentrations were determined by immunoassay, with a sensitivity of 0.1 ng/ml.

Results: The mean NAF volume obtained and the mean NAF protein concentration were no different in the normal versus the affected breast (62.4 versus 60.4 µl and 140.9 versus 107.8 mg/ml, respectively). Mean serum HER-2/neu level was 4.36 ng/ml (range, 0–16.8 ng/ml), 50 times less than the mean NAF HER-2/neu level from all patients and all breasts (209.2 ng/ml; range, 1.0–3480.0). NAF HER-2/neu levels were significantly correlated between breasts for each individual patient (r = 0.302; P = 0.038). HER-2/neu-overexpressing tumors produced significantly more HER-2/neu in the affected breast (653.6 ng/ml) than in the unaffected breast (101.7 ng/ml) or serum (3.46 ng/ml; P = 0.016).

Conclusions: Nipple aspiration is a noninvasive method for detecting tumor-specific relevant molecular changes from ductal fluid. The presence of high HER-2/neu levels in the ductal systems of breast cancer patients may have clinical implications for monoclonal antibody directed therapy.

This article has been cited by other articles:

				R. S. Dua, C. M. Isacke, and G. P.H. Gui The Intraductal Approach to Breast Cancer Biomarker Discovery J. Clin. Oncol., March 1, 2006; 24(7): 1209 - 1216. [Abstract] [Full Text] [PDF]

				M. R. Sartippour, L. Zhang, M. Lu, H.-J. Wang, and M. N. Brooks Nipple Fluid Basic Fibroblast Growth Factor in Patients with Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2995 - 2998. [Abstract] [Full Text] [PDF]

				C. Streckfus and L. Bigler The Use of Soluble, Salivary c-erbB-2 for the Detection and Post-operative Follow-up of Breast Cancer in Women: The Results of a Five-year Translational Research Study Advances in Dental Research, June 1, 2005; 18(1): 17 - 24. [Full Text] [PDF]